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Abstract
Background: Rheumatoid arthritis (RA) is classified as seropositive or seronegative, depending on the presence/
absence of rheumatoid factor (RF), primarily IgM RF, and/or anti-citrullinated protein antibodies (ACPA), commonly
detected using anti-cyclic citrullinated peptide (CCP) assays. Known risk factors associate with the more severe
seropositive form of RA; less is known about seronegative RA. Here, we examine risk factors and clinical phenotypes
in relation to presence of autoantibodies in the RA subset that is traditionally defined as seronegative.
Methods: Anti-CCP2 IgG, 19 ACPA fine-specificities, IgM/IgG/IgA RF, anti-carbamylated-protein (CarP) antibodies,
and 17 other autoantibodies, were analysed in 2755 RA patients and 370 controls. Antibody prevalence, levels, and
co-occurrence were examined, and associations with risk factors and disease activity during 5 years were
investigated for different antibody-defined RA subsets.
Results: Autoantibodies were detected in a substantial proportion of the traditionally defined seronegative RA subset,
with ACPA fine-specificities found in 30%, IgA/IgG RF in 9.4%, and anti-CarP antibodies in 16%, with a 9.6% co-occurrence
of at least two types of RA-associated autoantibodies. HLA-DRB1 shared epitope (SE) associated with the presence of
ACPA in anti-CCP2-negative RA; in anti-CCP2-positive RA, the SE association was defined by six ACPA fine-specificities
with high co-occurrence. Smoking associated with RF, but not with ACPA, in anti-CCP2-negative RA. Presence of ACPA
and RF, but not anti-CarP antibodies, in conventionally defined “seronegative” RA, associated with worse clinical outcome.
Conclusions: “Seronegative” RA is not truly a seronegative disease subset. Additional screening for ACPA fine-specificities
and IgA/IgG RF defines a group of patients that resembles seropositive patients with respect to risk factors and clinical
picture and may contribute to earlier diagnosis for a subset of anti-CCP2−/IgM RF− patients with a high need for active
treatment.
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Introduction
Presence of anti-citrullinated protein antibodies (ACPA)
is a hallmark of rheumatoid arthritis (RA), and together
with rheumatoid factor (RF), part of the 2010 American
College of Rheumatology (ACR)/European League
Against Rheumatism (EULAR) classification criteria [1].
Patients positive for ACPA and/or RF may be referred to
as “seropositive” and make up approximately two thirds
of the RA population. Seropositive and seronegative RA
seem to have disparate mechanisms in predisposition,
since HLA-DRB1 shared epitope (SE) alleles, as well as a
number of other genes, associate primarily with ACPA-
positive RA [2, 3], while other genes have been linked to
ACPA-negative disease [4], suggesting that these subsets
are partly separate disease entities.
While typically considered having a less inflammatory
and less destructive form of RA [5], seronegative patients
require more clinical symptoms to be classified as having
RA according to the 2010 ACR/EULAR criteria [1],
compared to seropositive patients, and may conse-
quently be diagnosed later [6]. Since all patients benefit
from early treatment, early diagnosis is critical also for
seronegative patients [7–9]. A major obstacle to this is
the lack of biomarkers.
ACPA status is commonly determined using assays
based on cyclic citrullinated peptides (CCP), such as the
“second generation” CCP2 test. However, these tests
utilise synthetic peptides as surrogate markers for
in vivo citrullinated antigens, while recent years have
seen a number of studies describing ACPA targets on
defined proteins (e.g. citrullinated fibrinogen [10],
vimentin [11], collagen type II (CII) [12], α-enolase [13],
histones [14], and tenascin C [15]). Since the CCP2 test
does not capture all ACPA, multiplex assays capable of
detecting multiple ACPA fine-specificities simultan-
eously may be useful, as more patients could potentially
be categorised as ACPA-positive/seropositive [14, 16–
19]. Using such a multiplex citrullinated peptide array,
we have recently shown that 16% of anti-CCP2-negative
RA patients were in fact ACPA-positive [19].
The other major autoantibody in RA, RF, is most often
defined as IgM directed against the constant region of
IgG, although other RF isotypes (mainly IgG and IgA)
are also present in subsets of patients, but generally not
screened for in the clinic [20]. More recently, antibodies
to carbamylated proteins (anti-CarP antibodies) have
been described in RA [21], and additional autoanti-
bodies, including anti-nuclear antibodies, which are
primarily linked to other rheumatic/autoimmune condi-
tions, have also been detected in subsets of RA [22].
In this study, we have used the Swedish population-
based RA case-control study EIRA (Epidemiological In-
vestigation of RA) as a basis for the analysis of autoanti-
bodies present in the RA subset conventionally defined
as seronegative, and we have investigated whether the
presence of such antibodies associates with classical RA
risk factors and have predictive value for disease activity.
Patients and methods
Study population
This study includes newly diagnosed RA based on the
1987 revised ACR criteria [23] and age-, sex-, and resi-
dential area-matched controls from the Swedish
population-based EIRA cohort [24]. Information on
smoking was collected via self-reported questionnaire at
baseline; individuals were categorised as “ever smokers”
(including current and former smokers) or “never
smokers”. Patients and controls donated blood at inclu-
sion and were genotyped for HLA-DRB1 alleles and
PTPN22 (rs2476601) polymorphism as previously de-
scribed [25, 26]. HLA-DRB1*01 (except DRB1*0103),
*04, and *10 were classified as SE. Data on smoking and
genetics were available for 2198 RA patients and 2797
controls. Baseline disease activity score for 28 joints
(DAS28) and C-reactive protein (CRP) levels (mg/L)
were captured on 1986 and 2096 RA patients, respect-
ively, by linking EIRA with the Swedish Rheumatology
Quality register [27]. Five-year clinical follow-up data
(DAS28-CRP) was analysed in 1086 RA patients.
This study has been performed in compliance with the
Declaration of Helsinki, with informed consent obtained
from all participants, and ethical approval granted at the
Regional Ethical Review Board in Stockholm.
Antibody detection: multiplex microarray and ELISA
High-throughput IgG screening was performed on sera
from 2755 RA cases and 370 controls using a custom-
made microarray chip (Thermo Fisher Scientific, Immu-
noDiagnostics), as previously described [18]. Antigens
included 19 citrullinated peptides (and arginine-
containing equivalents) from filaggrin, fibrinogen,
vimentin, α-enolase, collagen type II (CII), and heteroge-
neous nuclear ribonucleoprotein-A3 (hnRNP-A3), and
17 non-citrullinated antigens reported as autoantibody
targets in other rheumatic/autoimmune disorders (Add-
itional files 1 and 2). Cutoff (for each antibody) was set
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based on reactivity among controls and correspond to
the highest 98th percentile found in 20 randomly se-
lected subsets comprising 80% of the control population.
Anti-CCP2 IgG was measured using Immunoscan
CCPlus® ELISA (Euro-Diagnostica AB, Malmö, Sweden),
according to the manufacturer’s instructions, with a cut-
off of 25 U/mL. IgM, IgG, and IgA RF were analysed
using EliA™ immunoassay on Phadia 2500 (Phadia AB,
Uppsala, Sweden), using cutoff values as stated in the
manufacturer’s instructions. Anti-carbamylated fibrino-
gen antibodies were measured in a subset of patients
(n = 1944), as previously reported [28], with cutoff set at
the 98th percentile among 316 EIRA controls.
Statistical methods
Differences in antibody levels/prevalence and DAS28-
CRP were analysed by Mann-Whitney U test. Co-
occurrence of ACPA and comparison of correlation co-
efficients between different ACPA fine-specificities in
anti-CCP2-positive and anti-CCP2-negative RA were
calculated using Pearson’s correlation (Rv.3.3.3), among
patients that were positive for at least one ACPA fine-
specificity. Associations between RA subsets and risk
factors were determined by unconditional logistic regres-
sion and presented as odds ratios (OR) with 95% confi-
dence intervals (CI) (SAS 9.4). Analyses were adjusted
for age, sex, and residential area, and PTPN22, smoking,
and SE when appropriate.
Results
Comparison of ACPA fine-specificities in anti-CCP2-
positive and anti-CCP2-negative RA
EIRA cases were first divided based on anti-CCP2 IgG
status, and anti-CCP2-positive patients were younger,
more frequently smokers, and carriers of HLA-DRB1 SE
and PTPN22 rs2476601, while there were no differences
with regard to baseline DAS28, CRP, or the female-to-
male ratio, as compared to anti-CCP2-negative patients
(Additional file 3).
As we have recently shown, using the multiplex citrul-
linated peptide array, ACPA fine-specificities can be de-
tected in a substantial proportion (16%) of the anti-
CCP2-negative EIRA RA population [19], also in line
with previous data [16, 17]. In this extended analysis, we
show that the pattern of citrulline-reactivity is similar
for anti-CCP2-negative and anti-CCP2-positive RA, al-
beit with lower prevalence, levels, and co-occurrence of
ACPA fine-specificities. Eleven out of 19 ACPA fine-
specificities were detected in anti-CCP2-negative RA, in
frequencies significantly above controls, while all 19
ACPA were detected in anti-CCP2-positive RA (Table 1).
The citrullinated fibrinogen-derived peptide Cit-Fibß60–
Table 1 ACPA fine-specificities in anti-CCP2+ and anti-CCP- RA and controls
ACPA fine-
specificities
Antibody frequencies (%) Antibody levels (median)a
CCP2+ CCP2− Controls p valueb CCP2+ CCP2− p valuec
Cit-Fibß60–74 80.6 9.5 0.8 < 0.0001 195.3 27.1 < 0.0001
Cit-peptide-5 75.4 8.6 1.1 < 0.0001 81.4 27.2 < 0.0001
Cit-peptide-Z1 69.3 5.1 0.5 0.0001 167.4 38.6 < 0.0001
Cit-Fibß36–52 65.6 5.0 1.4 0.003 605.0 186.4 < 0.0001
Cit-Vim60–75 63.5 2.9 1.1 0.049 641.6 321.9 0.009
CEP-1 60.9 4.4 1.1 0.003 678.2 316.1 < 0.0001
cfc1-cyc (CCP1) 59.9 3.8 1.1 0.009 514.7 166.0 < 0.0001
Cit-Fibα563–583 57.6 2.5 1.1 0.10 444.8 144.0 0.002
Cit-peptide-Z2 49.5 2.9 0.3 0.003 150.9 58.6 0.002
Cit-peptide-1 45.0 4.7 1.9 0.02 72.7 29.2 < 0.0001
Cit-Fibα621–635 42.9 4.6 1.4 0.005 384.0 123.0 < 0.0001
Cit-peptide-Bla26 39.9 4.4 1.4 0.006 80.3 48.7 0.003
Cit-Vim2–17 40.3 2.6 1.4 0.16 75.9 72.8 0.712
Cit-F4(Cit-Cit) 36.1 3.4 1.6 0.08 84.9 60.6 0.032
Cit-F4(R-Cit) 29.9 2.1 1.4 0.36 86.4 80.6 0.366
Cit-Fibα580–600 24.2 2.8 1.4 0.11 264.2 197.2 0.024
Cit-Fibα36–50 17.6 4.0 1.9 0.053 422.9 265.5 < 0.0001
Cit-C1 10.8 1.9 1.4 0.48 69.3 87.9 0.383
Cit-F4(Cit-R) 6.2 1.8 1.1 0.34 403.0 306.5 0.382
aMedian antibody levels are shown for ACPA+ patients only. P values indicate differences between banti-CCP2− RA and controls or between canti-CCP2+ and
anti-CCP2− RA
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74 was the most commonly detected fine-specificity in
both subsets, followed by Cit-peptide-5 and Cit-peptide-
Z1 derived from citrullinated hnRNP-A3 and Cit-
Fibß36–52 from fibrinogen. ACPA levels among ACPA
fine-specificity positive individuals were higher in anti-
CCP2-positive RA, compared to anti-CCP2-negative RA
(Table 1), and in anti-CCP2-negative RA, compared to
controls (Additional file 4). Co-occurrence of different
ACPA fine-specificities showed a similar correlation pro-
file for anti-CCP2-positive and anti-CCP2-negative sub-
sets (r2 = 0.65, p = 5.4e−22), with high correlation
between most ACPA, but an independent expression
pattern for some (e.g. Cit-Fibα36–50, Cit-Peptide-1, Cit-
F4Cit-R, and Cit-C1) (Fig. 1a, b). Co-occurrence of mul-
tiple ACPA was rare among controls; the majority
(84.1%) had only one ACPA fine-specificity, and none of
the controls had more than three. The number of citrul-
linated peptides recognised by control sera was signifi-
cantly lower than that of anti-CCP2-negative RA sera,
where 15% were positive for more than three ACPA,
and 32.7% were positive for two or three fine-
specificities (Fig. 1c, d).
Presence of RF in anti-CCP2-positive and anti-CCP2-
negative RA
In the present study, we have also analysed RF isotypes
IgM, IgG, and IgA in EIRA, and all RF isotypes were de-
tected in the anti-CCP2-negative subset, with IgM RF
present in 23.8%, IgG RF in 17.4%, and IgA RF in 10.6%
(Fig. 2a). Higher frequencies were detected in anti-
CCP2-positive RA: 89.6% (IgM RF), 75% (IgG RF), and
56.8% (IgA RF). IgM RF levels were higher in anti-
CCP2-positive, compared to anti-CCP2-negative pa-
tients, while no differences were observed for IgG and
IgA RF levels (Fig. 2b). Co-occurrence of at least two RF
isotypes was 47% among RF+/anti-CCP2− patients, and
all three isotypes were present in 25%; the corresponding
figures for RF+/anti-CCP2+ patients were 83% and 53%,
respectively (Fig. 2c). Co-occurrence of RF isotypes was
rare among RF-positive controls, and RF levels were sig-
nificantly lower than in patients.
Fig. 1 Co-occurrence of ACPA fine-specificities. a, b Correlation plots illustrating co-occurrence of different ACPA fine-specificities, in anti-CCP2-
positive and anti-CCP2-negative RA. Correlation (Pearson r2) between binary antibody expression vectors, among patients that were positive for at
least one ACPA fine-specificity, are shown; plotted using corrplot (v.0.77). The degree of correlation is illustrated in colours, according to Pearson’s
correlation coefficient (scale shown on the right). c, d The number of ACPA fine-specificities in anti-CCP2-negative RA and controls. The frequency
(%) of anti-CCP2-negative RA patients and controls with 1, 2–3, 4–10, or > 10 ACPA fine-specificities, and the number of ACPA per individual
patient/control, are shown. Only ACPA-positive individuals with higher reactivity against citrulline compared to arginine-containing peptides were
included in the analysis
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Presence of other autoantibodies in anti-CCP2-positive
and anti-CCP2-negative RA
In addition to ACPA fine-specificities and RF isotypes,
we have screened for the presence of 17 autoantibodies
primarily associated with other autoimmune rheumatic
diseases. In general, these other autoantibodies were
present at low frequencies in EIRA, with small differ-
ences between anti-CCP2-positive and anti-CCP2-
negative patients (Additional file 5). Six out of 17 (Ro60/
SSA, Ro52/SSA, PMScl100, La/SSB, U1-RNP-C, and
CENPB) were detected at significantly higher frequencies
in RA compared to controls, with antibodies against
Ro60/SSA and Ro52/SSA as the most common, both
with a frequency of 5.3% in anti-CCP2-negative RA and
4.8% and 3.4%, respectively, in anti-CCP2-positive RA.
Narrowing the “serological gap”
When combining ACPA, RF, and other autoantibodies,
we detect autoantibodies in 59.8% of the anti-CCP2-
negative RA population, with ACPA fine-specificities
found in 34.5%, RF isotypes in 30.1%, and other auto-
antibodies in 30.3%. Notably, considering the high num-
ber of autoantibodies investigated (n = 39), each with an
individual cutoff set between the 95th and 98th
Fig. 2 Autoantibody data in anti-CCP2-positive RA, anti-CCP2-negative RA, and controls. a Prevalence of IgM, IgG, and IgA RF. b Median IgM, IgG,
and IgA RF levels among RF-positive individuals; asterisks (*) indicate significantly lower IgM, IgG, and IgA RF levels in controls compared to RA
patients (p < 0.0001 for all). c Co-occurrence of different RF isotypes among RF-positive individuals, in anti-CCP2-positive RA (n = 1655/1766), anti-
CCP2-negative RA (n = 298/989), and controls (n = 39/370). d Prevalence of different autoantibody groups (ACPA, RF, and other autoantibodies).
e Co-occurrence of different autoantibody groups among autoantibody-positive individuals, in anti-CCP2-positive RA (n = 1753/1766), anti-CCP2-
negative RA (n = 591/989), and controls (n = 137/370)
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percentile, autoantibodies were also detected in 37% of
the control population, with ACPA in 15.8%, RF in
10.5%, and other autoantibodies in 19%. Importantly, co-
occurrence of ACPA and RF was 15.7% in anti-CCP2-
negative RA, compared to only 2.7% in controls. For an
illustration of the distribution of ACPA, RF, and other
autoantibodies in anti-CCP2-positive RA, anti-CCP2-
negative RA, and controls, see Fig. 2d and e.
Autoantibodies in relation to RA risk factors
Classical RA risk factors HLA-DRB1 SE, PTPN22 poly-
morphism, and cigarette smoking are known to associate
with the anti-CCP2-positive subset of RA [26, 29]. In
addition, we and others have shown associations between
SE and the presence of ACPA in anti-CCP2-negative RA.
Here we can confirm an association between SE and
ACPA+/anti-CCP2− RA, while there was no significant as-
sociation between SE and the presence of RF or other auto-
antibodies in anti-CCP2-negative RA (Table 2). Smoking,
on the other hand, did not associate with ACPA, or other
autoantibodies, but showed a significant association with
RF in anti-CCP2-negative RA. PTPN22 polymorphism as-
sociated significantly with all anti-CCP2-negative RA sub-
sets, irrespective of autoantibody status (Additional file 6).
Based on these data, we proceeded to investigate associ-
ations between SE and individual ACPA fine-specificities
further, as well as associations between smoking and dif-
ferent RF isotypes, in both anti-CCP2-positive and anti-
CCP2-negative RA subsets.
In anti-CCP2-positive RA, SE associated with all individ-
ual ACPA fine-specificities, in line with what we have pre-
viously shown in RA [19]. In our extended analysis, we
found that the SE association was significantly stronger in
the presence of ACPA reactive with Cit-Fibβ60–74, Cit-
peptide-5, Cit-peptide-Z1, Cit-Vim60–75, CEP-1, and Cit-
Vim2–17, than in the absence of these six ACPA fine-
specificities (Additional file 7); two of these ACPA fine-
specificities (Cit-Fibβ60–74 and Cit-Vim60–75) also showed
significant associations with SE in anti-CCP2-negative RA.
The association with smoking was significantly stron-
ger in the presence of IgG and IgA RF in anti-CCP2-
positive RA and in the presence of IgM and IgA RF in
anti-CCP2-negative RA, than in the absence of these RF
isotypes (Additional file 8). Moreover, in a sub-analysis,
comparing never, current, and former smokers in the
whole RA population, we observed significantly higher
RF levels (all isotypes) and anti-CCP2 IgG levels in
current and former smokers, compared to never
smokers (p < 0.0001) (Additional file 9). However, when
comparing current to former smokers, only RF levels (all
isotypes) were significantly elevated (p < 0.0001 for IgM
and IgA RF; p = 0.0003 for IgG RF), while anti-CCP2
IgG levels (p = 0.1532) and ACPA fine-specificity levels
(data not shown) did not differ significantly.
Presence of RA-associated autoantibodies in
“seronegative” RA
In a subset of EIRA (n = 1944), we have previously inves-
tigated the presence of anti-CarP antibodies, which we
Table 2 Associations between autoantibodies and risk factors, in anti-CCP2− RA
Subgroup Exposure
SE− SE+ OR (95% CI)a OR (95% CI)b
Controls 1341 1456 1.0 (ref) 1.0 (ref)
ACPA− 246 265 0.99 (0.82–1.2) 1.00 (0.83–1.21)
ACPA+ 126 176 1.29 (1.01–1.64) 1.30 (1.02–1.65)
RF− 258 293 1.04 (0.87–1.26) 1.05 (0.88–1.27)
RF+ 114 148 1.20 (0.93–1.55) 1.21 (0.94–1.57)
Other Ab− 242 316 1.20 (1.00–1.45) 1.22 (1.01–1.46)
Other Ab+ 130 125 0.88 (0.68–1.14) 0.89 (0.69–1.15)
Never smoker Ever smoker OR (95% CI)a OR (95% CI)c
Controls 1208 1589 1.0 (ref) 1.0 (ref)
ACPA− 184 327 1.35 (1.11–1.64) 1.34 (1.10–1.63)
ACPA+ 121 181 1.16 (0.91–1.48) 1.15 (0.90–1.47)
RF− 221 330 1.13 (0.94–1.36) 1.13 (0.93–1.36)
RF+ 84 178 1.65 (1.26–2.16) 1.63 (1.24–2.14)
other Ab- 203 355 1.33 (1.10–1.60) 1.32 (1.09–1.59)
other Ab+ 102 153 1.16 (0.89–1.51) 1.16 (0.89–1.51)
Odds ratios were adjusted for aage, sex, and residential area, bPTPN22 and smoking, or cSE and PTPN22. ACPA = any ACPA fine-specificity; RF = IgM and/or IgG
and/or IgA RF; other Ab = any other autoantibody
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detected in 43% of RA patients [28]. Now we focused
the analysis on the traditionally defined “seronegative”
subset of EIRA, i.e. anti-CCP2 IgG−/IgM RF− patients
(n = 534), and found anti-CarP antibodies in 15.9%,
ACPA fine-specificities in 29.8%, and IgA and/or IgG RF
in 9.4%, with a co-occurrence of at least two types of
RA-associated autoantibodies in 9.6% (Table 3). When
combining ACPA, RF, and anti-CarP antibodies, 43.6%
of the “seronegative” RA patients were in fact
“seropositive”.
RA-associated autoantibodies in relation to disease
course in “seronegative” RA
We then investigated the impact of RA-associated auto-
antibodies on disease course in “seronegative” RA during
a 5-year follow-up period. Compared to patients that
were negative for all investigated RA-associated auto-
antibodies, the presence of ACPA fine-specificities and/
or IgG/IgA RF and/or anti-CarP antibodies (in the anti-
CCP2−/IgM RF− subset) associated with higher DAS28
during follow-up (Table 4). This observation seemed to
be dependent on the presence of ACPA and RF, but not
anti-CarP antibodies. Significantly higher DAS28 scores
were recorded in the ACPA+/anti-CCP2−/IgM RF− sub-
set (median DAS28: 3.66 versus 1.96, p = 0.002) and in
the IgA/IgG RF+/anti-CCP2−/IgM RF− subset (median
DAS28: 3.17 versus 1.96, p = 0.03) at 48 months. Highest
DAS28 was found in the ACPA+/anti-CarP−/anti-CCP2
−/IgM RF− subset (median DAS28: 3.23 versus 2.14, p =
0.03 at 36 months, and 3.69 versus 1.96, p = 0.007, at 48
months). Notably, DAS28 was as high (or even higher)
in this subset as in the traditionally defined seropositive
subset (i.e. anti-CCP2+ and/or IgM RF+). Lowest DAS28
scores during follow-up were noted in ACPA−/anti-
CarP+/anti-CCP2−/IgM RF− patients.
Discussion
We find autoantibodies in “seronegative” RA, at signifi-
cantly higher frequencies, levels, and co-occurrence
compared to controls, and with a similar pattern of re-
activity as in traditionally defined seropositive RA, albeit
with a narrower serology in regards to RA-associated
autoantibodies. Our data are thus in line with previous
studies demonstrating the presence of ACPA in anti-
CCP2-negative RA [16, 17, 19] and a recent report, de-
tecting IgA RF and anti-CCP2 IgA in 5.2% of “seronega-
tive” RA [30]. A novel finding in our study is that the
extended ACPA/RF serology defines a group of RA pa-
tients with a more severe prognosis, and since additional
screening of ACPA fine-specificities and IgA/IgG RF was
able to identify 35% of the patients in the conventionally
defined seronegative RA subset, our data suggest that
the use of such extended serology may be clinically
useful.
While the presence of ACPA fine-specificities and RF
in “seronegative” RA associated with higher disease ac-
tivity during follow-up, the presence of anti-CarP anti-
bodies associated with lower disease activity in our
study. This observation is somewhat contradictory to
what has been reported previously, where presence of
anti-CarP antibodies was shown to associate with higher
disease activity and worse clinical outcome [21, 31, 32].
However, the other studies have either only analysed
baseline DAS28, and at baseline, we also found a non-
significant trend with higher disease activity in the anti-
CarP-positive group, or the other studies have analysed
radiological progression over time, while we have ana-
lysed DAS28 over time, with no access to radiological
data. Moreover, the other studies did not investigate
presence of ACPA fine-specificities. Based on our data,
nearly 40% of anti-CarP-positive patients within the
“seronegative” RA population would also be ACPA-
positive. Therefore, it cannot be ruled out that the ob-
served joint destruction in the other studies is primarily
associated with ACPA, rather than anti-CarP antibodies.
In accordance with data published by Wagner et al.
[17], as well as our recent report [19], we found an asso-
ciation of SE with the presence of ACPA in anti-CCP2-
negative RA, suggesting that these patients belong to the
same disease entity as anti-CCP2-positive patients. A
more detailed analysis of the ACPA fine-specificity re-
sponse showed that SE associates primarily with some
ACPA fine-specificities, not all. These ACPA fine-
specificities co-occurred to a large extent, which could
possibly indicate cross-reactivity rather than co-
occurrence, something that has been shown on a mono-
clonal level for different ACPA [33–35]. Other ACPA
did not co-occur to the same extent, which may suggest
different triggering mechanisms for different ACPA fine-
specificities. This, we have recently explored in a separ-
ate study, demonstrating unique genetic characteristics
for different ACPA fine-specificities [36]. We did not
find an association between HLA-DRB1 SE and RF in
Table 3 RA-associated autoantibodies in “seronegative” RA









aAntibody status was evaluated in 534 anti-CCP2 IgG−/IgM RF− EIRA patients.
ACPA = any ACPA fine-specificity, RF = IgA and/or IgG RF, anti-CarP = anti-
carbamylated fibrinogen antibodies
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anti-CCP2-negative RA, supporting data generated from
single-cell RNA sequencing of RF-positive and ACPA-
positive B cells, which suggest a T cell-dependent affinity
maturation for the generation of ACPA, but innate im-
mune pathways for the generation of RF [37].
We could not detect an association between smok-
ing and presence of ACPA in anti-CCP2-negative RA,
but a significant association with RF, in particular IgA
RF. We also observed significantly elevated RF (but
not anti-CCP2 IgG) levels in current smokers com-
pared to former smokers. These data are thus in line
with recent reports, demonstrating a lack of associ-
ation between ACPA and smoking in RF-negative RA
[38] and that the association between smoking and
RA-associated antibodies is likely dependent on RF/
RF levels [39]. The association between smoking and
IgA RF is well known [40, 41] and points to the puta-
tive role of mucosal inflammation in the generation
of IgA RF. Notably, RF has been reported in healthy
smokers [41, 42].
Contrary to ACPA and RF, the other autoantibodies—
not primarily associated with RA—were low in fre-
quency, equally distributed among anti-CCP2-positive
and anti-CCP2-negative RA patients, and showed no as-
sociations with genetic and environmental risk factors.
Most common were anti-R060/SSA and anti-Ro52/SSA
antibodies, each with a frequency of around 5%, similar
to previous reports [43]. Their presence may indicate
clinical features associated with other systemic inflam-
matory diseases, in addition to classical RA symptoms.
Although the PTPN22 polymorphism (rs2476601) was
more frequent among anti-CCP2-positive patients com-
pared to anti-CCP2-negative, we found a significant as-
sociation with both subsets, similar to previous reports
[44, 45]. Presence/absence of ACPA fine-specificities,
RF, and other autoantibodies did not affect this positive
association. PTPN22 polymorphism has been described
as a risk factor for several autoimmune diseases [46],
and healthy carriers have been reported to have more
autoreactive B cells compared to non-carriers [47].
Hence, the association of PTPN22 with autoantibody-
negative RA was a bit surprising and potentially suggests
the presence of yet other autoimmune reactions.
Our study is by no means complete when it comes to
the analysis of RA-associated autoantibodies. We did not
investigate the presence of anti-CCP2 IgA [48] nor did
we analyse presence of ACPA using other commercial
clinical tests, like the CCP3/CCP3.1 assays or the mu-
tated citrullinated vimentin (MCV) assay. The antibody
response against human PAD enzymes [49] and acety-
lated proteins [50] was not investigated either, and anti-
CarP antibodies were analysed using carbamylated fi-
brinogen as an antigen [28], while other studies have
used carbamylated foetal calf serum [21, 39].
Another point to be considered is the loss of specificity
when analysing multiple autoantibody reactivities.
Hence, for a diagnostic setting, highly specific cutoff
values should be strictly applied to each individual anti-
body and be based not only on population controls but
on disease controls with other rheumatic and
Table 4 Disease activity during 5-years follow-up, in relation to autoantibody status
RA subseta 0 m 3m 6m 12m 24m 36m 48m 60m
Seronegative DAS28 5.10 3.49 3.25 2.72 2.33 2.14 1.96 2.2.11
n 163 138 139 154 148 73 47 103
Ab+ DAS28 5.37 3.59 3.34 2.80 2.68 2.63 2.97 2.02
n 123 110 107 119 104 56 35 62
ACPA+ DAS28 5.34 3.63 3.41 2.94 2.71 2.99 3.66 2.20
n 87 77 79 84 75 40 21 41
RF+ DAS28 5.50 3.67 3.49 2.49 2.27 2.61 3.17 1.88
n 27 23 23 26 24 13 8 12
Carb+ DAS18 5.50 3.30 3.35 2.77 2.66 2.13 2.20 1.78
n 43 38 33 40 33 16 14 24
ACPA+/Carb− DAS28 5.15 3.66 3.44 3.01 2.76 3.23 3.69 2.37
n 68 61 64 67 60 33 16 32
ACPA−/Carb+ DAS28 5.57 3.14 3.30 2.75 2.74 1.89 1.91 1.71
n 24 22 18 23 18 9 9 15
Seropositive DAS28 5.08 3.67 3.25 3.02 2.71 2.94 2.87 2.75
n 747 650 595 719 685 444 315 522
aAll RA subsets (with the exception of seropositive RA) are anti-CCP2 IgG−/IgM RF−; Ab+ = ACPA+, and/or IgA RF+, and/or IgG RF+, and/or anti-CarP+;
seropositive = anti-CCP2 IgG+ and/or IgM RF+. Median DAS28-CRP values are shown for each RA subset (significantly higher DAS28-CRP compared to seronegative
RA in bold). N = number of patients in each subset at each time point. 0 m = baseline; 3–60m = 3months to 60 months follow-up period
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autoimmune conditions. Still, our data suggest that the
number of ACPA fine-specificities, as well as co-
occurrence of ACPA and IgA/IgG RF, could be useful
diagnostic markers.
Conclusion
Our study confirms that seronegative RA, defined only
from the presence of anti-CCP2 IgG and IgM RF, is not
truly a seronegative disease subset. Presence of ACPA
and RF in the conventionally defined seronegative RA
population defines a group of patients that resemble
seropositive patients with respect to risk factors and
clinical picture. Thus, our data suggest that extended
ACPA and RF serology could be clinically useful in order
to capture patients early in the disease process and to
identify a subset with a high need for active treatment.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13075-020-02191-2.
Additional file 1: Supplementary Table 1. Citrullinated peptide
antigens on the multiplex microarray. The table lists citrullinated antigens
used on the multiplex microarray, including name, protein of origin, and
amino acid sequence, as well as references.
Additional file 2: Supplementary Table 2. Other (non-citrullinated)
autoantigens on the multiplex microarray. The table lists the other
antigens used on the multiplex microarray, including name, protein of
origin, and major associated disease(s).
Additional file 3: Supplementary Table 3. Baseline characteristics in
CCP2-positive and -negative RA. The table show baseline characteristics
for the EIRA patients included in the study, based on anti-CCP2 IgG sta-
tus; p-values indicate differences between subsets with respect to: age,
female-to-male ratio, number of smokers, HLA-DRB1 SE-positivity,
PTPN22-positivity, DAS28 and CRP.
Additional file 4: Supplementary Figure 1. ACPA fine-specificity levels
in anti-CCP2-negative RA and controls. ACPA levels for 19 individual
ACPA fine-specificities are shown in separate graphs with AU values on
the Y-axes. Only ACPA levels above cutoff for positivity are shown.
Additional file 5: Supplementary Table 4. Other autoantibodies in
anti-CCP2-positive and -negative RA and controls. Frequencies of 17
other autoantibodies in anti-CCP2-positive RA, anti-CCP2-negative RA and
controls are shown, as well as median antibody levels in anti-CCP2-
positive and -negative RA (p-values indicate differences between anti-
CCP2-negative and anti-CCP2-positive RA subsets).
Additional file 6: Supplementary Table 5. Associations between
different autoantibodies and PTPN22 polymorphism, in anti-CCP2-
negative RA. Odds ratios with 95% confidence intervals are shown for as-
sociations between PTPN22 polymorphism and presence/absence of
ACPA, RF, other autoantibodies, or "any autoantibody" in anti-CCP2-
negative RA.
Additional file 7: Supplementary Table 6. Associations between
different ACPA fine-specificities and HLA-DRB1 SE, in anti-CCP2-positive
and anti-CCP2-negative RA. Odds ratios with 95% confidence intervals are
shown for associations between HLA-DRB1 SE and presence/absence of
19 different ACPA fine-specificities, in anti-CCP2-positive and -negative
RA: p-values indicate differences in ORs between ACPA fine-specificity-
positive and -negative subsets in the anti-CCP2-positive subset.
Additional file 8: Supplementary Table 7. Associations between RF
isotypes and smoking, in anti-CCP2-positive and anti-CCP2-negative RA.
Odds ratios with 95% confidence intervals are shown for associations be-
tween smoking and presence/absence of IgM, IgG or IgA RF, in anti-
CCP2-positive and -negative RA; p-values indicate differences in ORs be-
tween RF isotype-positive and -negative subsets.
Additional file 9: Supplementary Figure 2. Antibody levels in EIRA
RA cases based on smoking status. IgM, IgG and IgA RF levels, as well as
anti-CCP2 IgG levels, are shown for never, current and former smokers in
all EIRA RA patients where smoking data was available.
Abbreviations
ACPA: Anti-citrullinated protein antibody; RA: Rheumatoid arthritis;
RF: Rheumatoid factor; ACR: American College of Rheumatology;
EULAR: European League Against Rheumatism; SE: Shared epitope;
CCP: Cyclic citrullinated peptide; CII: Type II collagen; Anti-CarP
antibody: Anti-carbamylated protein antibody; EIRA: Epidemiological
investigation of RA; DAS28: Disease activity score for 28 joints; CRP: C-
reactive protein; hnRNP-A3: Heterogeneous nuclear ribonucleoprotein-A3;
OR: Odds ratio; CI: Confidence interval; MCV: Mutated citrullinated vimentin
Acknowledgements
We wish to thank EIRA study participants and the EIRA study group for their
contributions; Professor Lars Klareskog for establishing the EIRA study: and
for support and scientific input; scientists previously involved in the
generation of data for the EIRA database: Leonid Padyukov, Patrick Stolt,
Camilla Bengtsson, and Lena Israelsson; Per Matsson, Mats Nystrand, and
Thomas Schlederer (Thermo Fisher Scientific, Uppsala, Sweden) for their
scientific support concerning the multiplex platform; and Karl Andersson for
calculating antibody cutoff values.
Authors’ contributions
ER had full access to all data, made statistical calculations, and produced
Table 1, Fig. 2, and supplementary Tables 3 and 4. AKH made all
unconditional logistic regression analyses for the gene-environment associa-
tions and produced Table 2 and supplementary Tables 5, 6, and 7. MH and
LMA performed the antibody screening on EIRA, using the peptide multiplex
array and EliA™. BB analysed correlations between ACPAs and produced
Fig. 1. SS retrieved clinical data from the Swedish Rheumatology Quality
register and performed the linkage with EIRA. MC, PJJ, RH, KS, and GS pro-
vided antigen peptides for the antibody analyses, including validation of
their performance. LA is responsible for administrating the EIRA study and
supervised the work of AKH and BB. JR contributed to the overall study de-
sign, analysed antibody levels in patients based on smoking status, analysed
DAS28 5-year follow-up data, and produced Table 4. KL conceived the study;
supervised the work of ER; produced Table 3, supplementary Tables 1 and 2,
and supplementary figure 1; wrote the manuscript together with ER; and
had overall responsibility for the study. All authors critically read, reviewed,
and approved the final manuscript.
Funding
This work was supported by grants from the Swedish Research Council
(2017-01696); King Gustav V:s 80-year foundation (FAI-2016-0273); the EU
funded consortia TRIGGER (FP7-Health-2013-306029); and the EU/EFPIA In-
novative Medicines Initiative Joint Undertaking BeTheCure (grant n° 115142),
and RTCure (grant n° 777357). Open access funding provided by Karolinska
Institute.
Availability of data and materials
All data generated during this study are included in this published article,
and in its supplementary information files, or are available from the
corresponding author on reasonable request. The EIRA dataset on which the
current study is based is deposited in the EIRA database at Karolinska
Institutet, Stockholm, Sweden.
Ethics approval and consent to participate
The study has been performed in compliance with the Declaration of
Helsinki, with informed consent obtained from all study participants, and
ethical approval granted at the Regional Ethical Review Board in Stockholm.
Consent for publication
Not applicable.
Reed et al. Arthritis Research & Therapy          (2020) 22:170 Page 9 of 11
Competing interests
The authors declare that they have no conflicting financial interest and have
not received funding from commercial sources in the context of this study.
Karolinska Institutet has been a partner with Thermo Fisher Scientific within
the Innovative Medicines Initiative BTCure, a public–private partnership
between the EU and the European Federation of Pharmaceutical Industries
(www.BTcure.eu). Thermo Fisher Scientific has contributed to this consortium
with in-kind contributions for the development of the microarray multiplex
assay used in the current study. LMA is employed by Thermo Fischer Scien-
tific. JR is a member of the Thermo Fisher Scientific advisory board.
RH is a co-inventor of the patent US Patent 7 148 020, protecting the use of
the CitC1 and C1 peptides. KS is co-inventor of patents US 13/141,960 and
EP 09799354.7, describing the diagnostic use of the hnRNP-A3 peptide epi-
topes. GS is co-inventor of several international patents about ACPA antigens
held by BioMérieux Cy and licenced to Eurodiagnostica Cy and Axis-Shield
Cy, for commercialization of the CCP2 assays; according to French laws, part
of the royalties is paid to the Toulouse III University and the University Hos-
pital of Toulouse. KL is co-inventor of the patent US12/524,465, describing
the diagnostic use of the CEP-1 epitope.
Author details
1Division of Rheumatology, Department of Medicine Solna, Karolinska
Institutet, Karolinska University Hospital, CMM L8:04, 171 76 Stockholm,
Sweden. 2Institute of Environmental Medicine, Karolinska Institutet,
Stockholm, Sweden. 3Department of Clinical Neuroscience, Karolinska
Institutet, Stockholm, Sweden. 4Thermo Fisher Scientific, Uppsala, Sweden.
5Department of Immunology Genetics and Pathology, Uppsala University,
Uppsala, Sweden. 6Division of Clinical Epidemiology, Department of
Medicine Solna, Karolinska Institutet, Stockholm, Sweden. 7Faculty of
Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
8Unité Différenciation Epithéliale et Autoimmunité Rhumatoïde, Université de
Toulouse-INSERM UMR 1056, Toulouse, France. 9Section for Medical
Inflammation Research, Department of Medical Biochemistry and Biophysics,
Karolinska Institutet, Stockholm, Sweden. 10Department of Rheumatology
and Clinical Immunology, Charité University, Berlin, Germany. 11Centre for
Occupational and Environmental Medicine, Region Stockholm, Stockholm,
Sweden.
Received: 12 September 2019 Accepted: 22 April 2020
References
1. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al.
2010 rheumatoid arthritis classification criteria: an American College of
Rheumatology/European League Against Rheumatism collaborative
initiative. Ann Rheum Dis. 2010;69(9):1580–8.
2. Kurreeman F, Liao K, Chibnik L, Hickey B, Stahl E, Gainer V, et al. Genetic
basis of autoantibody positive and negative rheumatoid arthritis risk in a
multi-ethnic cohort derived from electronic health records. Am J Hum
Genet. 2011;88(1):57–69.
3. Padyukov L, Seielstad M, Ong RTH, Ding B, Rönnelid J, Seddighzadeh M,
et al. A genome-wide association study suggests contrasting associations in
ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis.
2011;70(2):259–65.
4. Viatte S, Massey J, Bowes J, Duffus K, arcOGEN Consortium, Eyre S, et al.
Replication of associations of genetic loci outside the HLA region with
susceptibility to anti-cyclic citrullinated peptide-negative rheumatoid
arthritis. Arthritis Rheumatol. 2016;68(7):1603–13.
5. Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, et al.
Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP)
during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts
worse disease activity and greater radiological progression. Ann Rheum Dis.
2005;64(12):1744–9.
6. Nordberg LB, Lillegraven S, Lie E, Aga A-B, Olsen IC, Hammer HB, et al.
Patients with seronegative RA have more inflammatory activity compared
with patients with seropositive RA in an inception cohort of DMARD-naïve
patients classified according to the 2010 ACR/EULAR criteria. Ann Rheum
Dis. 2017;76(2):341–5.
7. Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, et al.
Patients lacking classical poor prognostic markers might also benefit from a
step-down glucocorticoid bridging scheme in early rheumatoid arthritis:
week 16 results from the randomized multicenter CareRA trial. Arthritis Res
Ther. 2015;17(1):97.
8. van Nies JAB, Krabben A, Schoones JW, Huizinga TWJ, Kloppenburg M, van
der Helm-van Mil AHM. What is the evidence for the presence of a
therapeutic window of opportunity in rheumatoid arthritis? A systematic
literature review. Ann Rheum Dis. 2014;73(5):861–70.
9. Westhoff G, Schneider M, Raspe H, Zeidler H, Runge C, Volmer T, et al.
Advance and unmet need of health care for patients with rheumatoid
arthritis in the German population--results from the German
Rheumatoid Arthritis Population Survey (GRAPS). Rheumatology (Oxford).
2009;48(6):650–7.
10. Masson-Bessière C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C,
Senshu T, et al. The major synovial targets of the rheumatoid arthritis-
specific antifilaggrin autoantibodies are deiminated forms of the alpha- and
beta-chains of fibrin. J Immunol. 2001;166(6):4177–84.
11. Vossenaar ER, Després N, Lapointe E, van der Heijden A, Lora M, Senshu T,
et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated
vimentin. Arthritis Res Ther. 2004;6(2):R142–50.
12. Burkhardt H, Sehnert B, Bockermann R, Engström A, Kalden JR, Holmdahl R.
Humoral immune response to citrullinated collagen type II determinants in
early rheumatoid arthritis. Eur J Immunol. 2005;35(5):1643–52.
13. Lundberg K, Kinloch A, Fisher BA, Wegner N, Wait R, Charles P, et al.
Antibodies to citrullinated alpha-enolase peptide 1 are specific for
rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum.
2008;58(10):3009–19.
14. Sokolove J, Bromberg R, Deane KD, Lahey LJ, Derber LA, Chandra PE, et al.
Autoantibody epitope spreading in the pre-clinical phase predicts
progression to rheumatoid arthritis. PLoS One. 2012;7(5):e35296.
15. Schwenzer A, Jiang X, Mikuls TR, Payne JB, Sayles HR, Quirke A-M, et al.
Identification of an immunodominant peptide from citrullinated tenascin-C
as a major target for autoantibodies in rheumatoid arthritis. Ann Rheum Dis.
2016;75(10):1876–83.
16. Lundberg K, Bengtsson C, Kharlamova N, Reed E, Jiang X, Källberg H, et al.
Genetic and environmental determinants for disease risk in subsets of
rheumatoid arthritis defined by the anticitrullinated protein/peptide
antibody fine specificity profile. Ann Rheum Dis. 2013;72(5):652–8.
17. Wagner CA, Sokolove J, Lahey LJ, Bengtsson C, Saevarsdottir S, Alfredsson L,
et al. Identification of anticitrullinated protein antibody reactivities in a
subset of anti-CCP-negative rheumatoid arthritis: association with cigarette
smoking and HLA-DRB1 ‘shared epitope’ alleles. Ann Rheum Dis. 2015;74(3):
579–86.
18. Hansson M, Mathsson L, Schlederer T, Israelsson L, Matsson P, Nogueira L,
et al. Validation of a multiplex chip-based assay for the detection of
autoantibodies against citrullinated peptides. Arthritis Res Ther. 2012;14(5):
R201.
19. Rönnelid J, Hansson M, Mathsson-Alm L, Cornillet M, Reed E, Jakobsson
P-J, et al. Anticitrullinated protein/peptide antibody multiplexing defines
an extended group of ACPA-positive rheumatoid arthritis patients with
distinct genetic and environmental determinants. Ann Rheum Dis. 2018;
77(2):203–11.
20. Vallbracht I, Rieber J, Oppermann M, Förger F, Siebert U, Helmke K.
Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies
compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann
Rheum Dis. 2004;63(9):1079–84.
21. Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GMC, van Veelen
PA, et al. Autoantibodies recognizing carbamylated proteins are present in
sera of patients with rheumatoid arthritis and predict joint damage. Proc
Natl Acad Sci U S A. 2011;108(42):17372–7.
22. Peene I, Meheus L, Veys EM, De Keyser F. Diagnostic associations in a large
and consecutively identified population positive for anti-SSA and/or anti-
SSB: the range of associated diseases differs according to the detailed
serotype. Ann Rheum Dis. 2002;61(12):1090–4.
23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al.
The American Rheumatism Association 1987 revised criteria for the
classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.
24. Stolt P, Bengtsson C, Nordmark B, Lindblad S, Lundberg I, Klareskog L, et al.
Quantification of the influence of cigarette smoking on rheumatoid arthritis:
results from a population based case-control study, using incident cases.
Ann Rheum Dis. 2003;62(9):835–41.
25. Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L. A gene-environment
interaction between smoking and shared epitope genes in HLA-DR
Reed et al. Arthritis Research & Therapy          (2020) 22:170 Page 10 of 11
provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum.
2004;50(10):3085–92.
26. Plenge RM, Padyukov L, Remmers EF, Purcell S, Lee AT, Karlson EW, et al.
Replication of putative candidate-gene associations with rheumatoid
arthritis in >4,000 samples from North America and Sweden: association of
susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet. 2005;77(6):
1044–60.
27. Saevarsdottir S, Wedrén S, Seddighzadeh M, Bengtsson C, Wesley A,
Lindblad S, et al. Patients with early rheumatoid arthritis who smoke are less
likely to respond to treatment with methotrexate and tumor necrosis factor
inhibitors: observations from the Epidemiological Investigation of
Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts.
Arthritis Rheum. 2011;63(1):26–36.
28. Jiang X, Trouw LA, van Wesemael TJ, Shi J, Bengtsson C, Källberg H, et al.
Anti-CarP antibodies in two large cohorts of patients with rheumatoid
arthritis and their relationship to genetic risk factors, cigarette smoking and
other autoantibodies. Ann Rheum Dis. 2014;73(10):1761–8.
29. Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson C, Grunewald J, et al.
A new model for an etiology of rheumatoid arthritis: smoking may trigger
HLA–DR (shared epitope)–restricted immune reactions to autoantigens
modified by citrullination. Arthritis Rheum. 2006;54(1):38–46.
30. Sieghart D, Platzer A, Studenic P, Alasti F, Grundhuber M, Swiniarski S, et al.
Determination of autoantibody isotypes increases the sensitivity of
serodiagnostics in rheumatoid arthritis. Front Immunol. 2018;9:876.
31. Truchetet M-E, Dublanc S, Barnetche T, Vittecoq O, Mariette X, Richez C,
et al. Association of the presence of anti-carbamylated protein
antibodies in early arthritis with a poorer clinical and radiologic
outcome: data from the French ESPOIR cohort. Arthritis Rheumatol.
2017;69(12):2292–302.
32. Derksen VFAM, Trouw LA, Huizinga TWJ, van der Helm-van Mil AHM, Knevel
R, Westerlind H, et al. Anti-carbamylated protein antibodies and higher
baseline disease activity in rheumatoid arthritis-a replication study in three
cohorts: comment on the article by Truchetet et al. Arthritis Rheumatol.
2018;70(12):2096–7.
33. Steen J, Forsström B, Sahlström P, Odowd V, Israelsson L, Krishnamurthy A,
et al. Recognition of amino acid motifs, rather than specific proteins, by
human plasma cell-derived monoclonal antibodies to posttranslationally
modified proteins in rheumatoid arthritis. Arthritis Rheumatol. 2019;71(2):
196–209.
34. Elliott SE, Kongpachith S, Lingampalli N, Adamska JZ, Cannon BJ, Mao R,
et al. Affinity maturation drives epitope spreading and generation of
proinflammatory anti-citrullinated protein antibodies in rheumatoid arthritis.
Arthritis Rheumatol. 2018;70(12):1946–58.
35. Ge C, Xu B, Liang B, Lönnblom E, Lundström SL, Zubarev RA, et al. Structural
basis of cross-reactivity of anti-citrullinated protein antibodies. Arthritis
Rheumatol. 2019;71(2):210–21.
36. Terao C, Brynedal B, Chen Z, Jiang X, Westerlind H, Hansson M, et al.
Distinct HLA associations with rheumatoid arthritis subsets defined by
serological subphenotype. Am J Hum Genet. 2019; in press. https://doi.org/
10.1016/j.ajhg.2019.08.002.
37. Lu DR, McDavid AN, Kongpachith S, Lingampalli N, Glanville J, Ju C-H, et al.
T cell-dependent affinity maturation and innate immune pathways
differentially drive autoreactive B cell responses in rheumatoid arthritis.
Arthritis Rheumatol. 2018;70(11):1732–44.
38. Murphy D, Mattey D, Hutchinson D. Anti-citrullinated protein antibody
positive rheumatoid arthritis is primarily determined by rheumatoid factor
titre and the shared epitope rather than smoking per se. PLoS One. 2017;
12(7):e0180655.
39. van Wesemael TJ, Ajeganova S, Humphreys J, Terao C, Muhammad A,
Symmons DPM, et al. Smoking is associated with the concurrent presence
of multiple autoantibodies in rheumatoid arthritis rather than with anti-
citrullinated protein antibodies per se: a multicenter cohort study. Arthritis
Res Ther. 2016;18(1):285–10.
40. Mikuls TR, Hughes LB, Westfall AO, Holers VM, Parrish L, van der Heijde D,
et al. Cigarette smoking, disease severity and autoantibody expression in
African Americans with recent-onset rheumatoid arthritis. Ann Rheum Dis.
2008;67(11):1529–34.
41. Janssen KMJ, de Smit MJ, Brouwer E, de Kok FAC, Kraan J, Altenburg J, et al.
Rheumatoid arthritis-associated autoantibodies in non-rheumatoid arthritis
patients with mucosal inflammation: a case-control study. Arthritis Res Ther.
2015;17(1):174.
42. Korpilahde T, Heliövaara M, Knekt P, Marniemi J, Aromaa A, Aho K. Smoking
history and serum cotinine and thiocyanate concentrations as determinants
of rheumatoid factor in non-rheumatoid subjects. Rheumatology (Oxford).
2004;43(11):1424–8.
43. Schneeberger E, Citera G, Heredia M, Maldonado CJ. Clinical significance of
anti-Ro antibodies in rheumatoid arthritis. Clin Rheumatol. 2008;27(4):517–9.
44. Viatte S, Plant D, Bowes J, Lunt M, Eyre S, Barton A, et al. Genetic markers of
rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody
negative patients. Ann Rheum Dis. 2012;71(12):1984–90.
45. Bossini-Castillo L, de Kovel C, Källberg H, van ’t Slot R, Italiaander A, Coenen
M, et al. A genome-wide association study of rheumatoid arthritis without
antibodies against citrullinated peptides. Ann Rheum Dis. 2015;74(3):e15.
46. Zheng J, Ibrahim S, Petersen F, Yu X. Meta-analysis reveals an association of
PTPN22 C1858T with autoimmune diseases, which depends on the
localization of the affected tissue. Genes Immun. 2012;13(8):641–52.
47. Menard L, Saadoun D, Isnardi I, Ng Y-S, Meyers G, Massad C, et al. The
PTPN22 allele encoding an R620W variant interferes with the removal of
developing autoreactive B cells in humans. J Clin Invest. 2011;121(9):3635–
44.
48. Svärd A, Skogh T, Alfredsson L, Ilar A, Klareskog L, Bengtsson C, et al.
Associations with smoking and shared epitope differ between IgA- and IgG-
class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis.
Arthritis Rheumatol. 2015;67(8):2032–7.
49. Harris ML, Darrah E, Lam GK, Bartlett SJ, Giles JT, Grant AV, et al. Association
of autoimmunity to peptidyl arginine deiminase type 4 with genotype and
disease severity in rheumatoid arthritis. Arthritis Rheum. 2008;58(7):1958–67.
50. Juarez M, Bang H, Hammar F, Reimer U, Dyke B, Sahbudin I, et al.
Identification of novel antiacetylated vimentin antibodies in patients with
early inflammatory arthritis. Ann Rheum Dis. 2016;75(6):1099–107.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Reed et al. Arthritis Research & Therapy          (2020) 22:170 Page 11 of 11
